Differential Diagnosis in the Management of Acute Respiratory Infections through Point-of-Care Rapid Testing in a Post-Pandemic Scenario in Latin America: Special Focus on COVID-19, Influenza, and Respiratory Syncytial Virus

Author:

Alvarez-Moreno Carlos Arturo12ORCID,de Araújo Evaldo Stanislau Affonso34ORCID,Baumeister Elsa56,Nogales Crespo Katya A.7ORCID,Kalergis Alexis M.8910ORCID,Muñoz Medina José Esteban11ORCID,Tsukayama Pablo1213ORCID,Ugarte-Gil Cesar1214ORCID

Affiliation:

1. Unidad Infectologia, Facultad de Medicina, Universidad Nacional de Colombia, Bogota 111321, Colombia

2. Clínica Universitaria Colombia, Clínica Colsanitas, Bogota 111321, Colombia

3. Infectious Diseases Department at Hospital das Clínicas, University of São Paulo, São Paulo 05403-010, Brazil

4. Inspirali Educação, São Paulo 18683-205, Brazil

5. Biological Sciences Department, Faculty of Exact Sciences, National University of La Plata, La Plata B1900, Argentina

6. School of Bio and Nanotechnologies, National University of San Martin, San Martin B1650, Argentina

7. Policy Wisdom LLC, Quebradillas 00678-2705, Puerto Rico

8. Millennium Institute on Immunology and Immunotherapy, Santiago de Chile 8330025, Chile

9. Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago de Chile 8331010, Chile

10. Departamento de Endocrinología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile 8331010, Chile

11. Coordination of Quality of Supplies and Specialized Laboratories (CCILE), Mexican Social Security Institute (IMSS), Mexico City 07760, Mexico

12. Institute of Tropical Medicine Alexander von Humboldt (IMTAvH), Universidad Peruana Cayetano Heredia (UPCH), Lima 150135, Peru

13. School of Sciences and Engineering, Universidad Peruana Cayetano Heredia (UPCH), Lima 150135, Peru

14. School of Medicine, Universidad Peruana Cayetano Heredia (UPCH), Lima 150135, Peru

Abstract

This review provides a comprehensive summary of evidence to explore the role and value of differential diagnosis in the management of Acute Respiratory Infections (ARIs) through point-of-care (POC) rapid testing in a post-pandemic scenario, paying particular attention to coronavirus disease 2019 (COVID-19), influenza, and respiratory syncytial virus (RSV). The document builds on a review of literature and policies and a process of validation and feedback by a group of seven experts from Latin America (LATAM). Evidence was collected to understand scientific and policy perspectives on the differential diagnosis of ARIs and POC rapid testing, with a focus on seven countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. The evidence indicates that POC rapid testing can serve to improve ARI case management, epidemiological surveillance, research and innovation, and evidence-based decision-making. With multiple types of rapid tests available for POC, decisions regarding which tests to use require the consideration of the testing purpose, available resources, and test characteristics regarding accuracy, accessibility, affordability, and results turnaround time. Based on the understanding of the current situation, this document provides a set of recommendations for the implementation of POC rapid testing in LATAM, supporting decision-making and guiding efforts by a broad range of stakeholders.

Funder

Abbott Laboratories

Publisher

MDPI AG

Reference305 articles.

1. World Health Organization (WHO) (2023, August 13). Archived: WHO Timeline—COVID-19. Available online: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19.

2. U.S. Food & Drug Administration (2023, August 13). FDA Approves First Treatment for COVID-19, Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.

3. European Medicines Agency (2023, May 03). COVID-19 Treatments: Authorized. Available online: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/treatments-covid-19/covid-19-treatments-authorised.

4. United Nations (2023, August 13). WHO Chief Declares End to COVID-19 as a Global Health Emergency, UN News, Available online: https://news.un.org/en/story/2023/05/1136367.

5. U.S. Food and Drug Administration (FDA) (2023, August 12). Authorizations of Emergency Use of Certain Antiviral Drugs-Zanamivir and Oseltamivir Phosphate; Availability, Available online: https://www.federalregister.gov/documents/2009/08/04/E9-18568/authorizations-of-emergency-use-of-certain-antiviral-drugs-zanamivir-and-oseltamivir-phosphate.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3